Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Closed

Other

Learn More

To learn more, visit ClinicalTrials.Gov or contact Clinical Research at 864-560-6812.

Sponsor(s)

Mayo Clinic

Key Trial Criteria

For a patient to be eligible for participation in this study, all of the following criteria must apply.
- Age at least 18 years
- Laboratory confirmed diagnosis of infection with SARS-CoV-2
- Admitted to an acute care facility for the treatment of COVID-19 complications
- Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease
- Informed consent provided by the patient or healthcare proxy

Clinical Research Trials

Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

Key Trial Criteria

Key Inclusion Criteria